Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>CHIR 99021 trihydrochloride

CHIR 99021 trihydrochloride (Synonyms: CHIR-99021 trihydrochloride; CT99021 trihydrochloride)

Katalog-Nr.GC15642

Laduviglusib (CHIR-99021) Trihydrochlorid ist ein potentes und selektives GSK-3α/β Inhibitor mit IC50s von 10 nM und 6,7 nM. CHIR 99021 Trihydrochlorid zeigt eine >500-fache SelektivitÄt fÜr GSK-3 gegenÜber CDC2, ERK2 und anderen Proteinkinasen. CHIR 99021 Trihydrochlorid ist auch ein starker Aktivator des Wnt/β-Catenin-Signalwegs. CHIR 99021 Trihydrochlorid verstÄrkt die Selbsterneuerung embryonaler Stammzellen von Maus und Mensch. CHIR 99021 Trihydrochlorid induziert Autophagie.

Products are for research use only. Not for human use. We do not sell to patients.

CHIR 99021 trihydrochloride Chemische Struktur

Cas No.: 1782235-14-6

Größe Preis Lagerbestand Menge
5mg
49,00 $
Auf Lager
10mg
71,00 $
Auf Lager
25mg
146,00 $
Auf Lager
100mg
406,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

CHIR-99021 trihydrochloride (CT99021 trihydrochloride) is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; >500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.

CHIR-99021 inhibits human GSK-3β with Ki values of 9.8 nM[1]. CHIR-99021 is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that CHIR-99021 specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases[2]. In the presence of CHIR-99021 the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM CHIR-99021 with an IC50 of 4.9 μM[3].

In ZDF rats, a single oral dose of CHIR-99021 (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration[1]. CHIR99021 (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). CHIR99021 treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. CHIR99021 treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h[4].

References:
[1]. Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
[2]. Bennett CN, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004.
[3]. Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.
[4]. Wang X, et al. Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015 Apr 10;5:8566.

Bewertungen

Review for CHIR 99021 trihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CHIR 99021 trihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.